Liver Disease Treatments: The Global Market
December 20, 2011
Wellesley, Mass. – In a recent release, LIVER DISEASE TREATMENTS: THE GLOBAL MARKET (PHM057B) from BCC Research (www.bccresearch.com), total revenues for liver disease drugs were valued at $12 billion in 2011. This market is expected to grow at a compound annual growth rate (CAGR) of 3.3% to reach nearly $14.2 billion in 2016.
The liver disease drug market can be divided into three main regions – the U.S, Europe, and the rest of the world.
The U.S. region accounted for $4.2 billion in 2011, and after increasing at a CAGR of 3%, should surpass $4.9 billion in 2016.
The European region was valued at nearly $3.6 million in 2011 and, increasing at a CAGR of 1%, should reach more than $3.7 billion in 2016.
The rest of the world totaled $4.2 billion in 2011, and by 2016, this region should account for nearly $5.5 billion, a CAGR of 5.4%.
Liver disease is one of the major causes of morbidity in the U.S., and it affects people of all ages. It most frequently affects individuals between the ages of 40 and 60. The last 25 years of medical research in liver disease has resulted in major improvements in patient survival and quality of life, but it is critically important to make further progress to control the major toll liver disease places on human health and well-being. Numerous products at various stages of development have the potential to bring more profound and important changes in the liver disease treatment modality.
This report explores current and future strategies within the liver disease drug market, including market sizes, market leaders, market overview, and various other market factors, as well as the market for end users. The current state of the market, its setbacks, its innovations, and its future needs also are discussed.
Examining the areas of growth in the liver disease drug market from the point of view of manufacturers and users, this study will be of interest largely to the pharmaceutical and biopharmaceutical industries, clinics, hospitals, and research institutes.
Liver Disease Treatments: The Global Market( PHM057B )
Publish Date: Jan 2012
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.
BCC Library Membership Benefits
Unlimited Access to Market Research Reports for Academic Institutions and Corporations.
Custom Research
Tailored solutions across industries for your unique business needs.
More in Pharmaceuticals
- Global Bispecific Antibodies Market to Reach $22.3 Billion by 2030 as Immuno-Oncology Innovation and R&D Investment Accelerate
- Neuroprotective Agents Market to Reach $60.9 Billion by 2030 as Neurological Disease Burden and Aging Populations Drive Pharmaceutical Investment
- Radioligand Therapeutics Market to More Than Double to $4.8 Billion by 2030 as Targeted Cancer Treatments Gain Regulatory Momentum
- Global GLP-1 Analogues Market to Reach $268.4 Billion by 2030
- AI in Clinical Trials Poised for Rapid Growth with a 22.6% CAGR Forecast
Reports from Pharmaceuticals
Recent News
- Biometrics as a Service in Medical Devices to Reach $2.7 Billion by 2030, Driven by Remote Patient Monitoring Demand
- Protein Synthesis Research Market to Reach $42.8 Billion by 2031, Driven by Surging CGT Investment
- AI and Advanced Diagnostics Transform Cancer Detection Market Amid Rising Healthcare Investment
- Global Noninvasive Cancer Diagnostics Market to Reach $165.2 Billion by 2030 as Liquid Biopsy, AI-Enabled Screening and Multi-Cancer Detection Tests Transform Oncology
- Cloud Computing in Cell Biology, Genomics and Drug Development to Reach $15.6 Billion by 2030 as Biological Data Explosion Drives Demand